Literature DB >> 16202684

Hematopathologic findings in chronic idiopathic myelofibrosis.

Juergen Thiele1, Hans M Kvasnicka.   

Abstract

Until now scant knowledge was available about the dynamics of chronic idiopathic myelofibrosis (CIMF). However, follow-up studies are in keeping with a stepwise evolution starting with a prefibrotic (hypercellular) phase that progressively transforms into the classical fibro-osteosclerotic endstage with myeloid metaplasia. Prefibrotic CIMF is characterized by a granulocytic and megakaryocytic myeloproliferation lacking an increase in reticulin. Most conspicuous are abnormalities of megakaryopoiesis with regard to their histotopography and maturation. There is a more than 65% probability of progression from an early to advanced CIMF accompanied by increasing anemia, splenomegaly, and leuko-erythroblastosis. A significant relationship is recognizable among frequency, tortuosity, and luminal dilation of the microvessels and the extent of myelofibrosis. Quantity of CD34(+) progenitor cells in the bone marrow (BM) reveals a close association with advancement of disease (fibrosis, splenomegaly, anemia, peripheral blasts) and therefore prognosis. Cell kinetic studies show increased proliferation associated with a higher rate of apoptosis in initial (hypercellular) stages, as well as a reduced endoreduplicative activity of megakaryopoiesis and a blocked synthesis phase of the erythroid precursors. It is noteworthy that prefibrotic and early CIMF often present with a marked thrombocytosis mimicking essential thrombocythemia. Regarding prognosis, early CIMF is associated with a significantly more favorable survival than advanced stages.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16202684     DOI: 10.1053/j.seminoncol.2005.04.010

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

Review 1.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

Authors:  Bin Fu; Chi Young Ok; Maitrayee Goswami; Wei Xei; Jesse M Jaso; Tariq Muzzafar; Carlos Bueso-Ramos; Srdan Verstovsek; Guillermo Garcia-Manero; L Jeffrey Medeiros; Sa A Wang
Journal:  Ann Hematol       Date:  2013-05-10       Impact factor: 3.673

3.  The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

Review 4.  Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.

Authors:  Martha Wadleigh; Ayalew Tefferi
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

Review 5.  Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Authors:  Ayalew Tefferi; Radek Skoda; James W Vardiman
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

6.  CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis.

Authors:  Claudio Tripodo; Andrea Di Bernardo; Maria Paola Ternullo; Carla Guarnotta; Rossana Porcasi; Sabrina Ingrao; Umberto Gianelli; Emanuela Boveri; Emilio Iannitto; Giovanni Franco; Ada Maria Florena
Journal:  Haematologica       Date:  2008-11-23       Impact factor: 9.941

7.  Expression of the TEL-Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in mice.

Authors:  Michelle T Graham; Clare L Abram; Yongmei Hu; Clifford A Lowell
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

8.  Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Authors:  H Gisslinger; G Jeryczynski; B Gisslinger; A Wölfler; S Burgstaller; V Buxhofer-Ausch; M Schalling; M-T Krauth; A-I Schiefer; C Kornauth; I Simonitsch-Klupp; C Beham-Schmid; L Müllauer; J Thiele
Journal:  Leukemia       Date:  2015-12-29       Impact factor: 11.528

9.  Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.

Authors:  Shuchi Ghai; Sharada Rai
Journal:  South Asian J Cancer       Date:  2017 Apr-Jun
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.